(March 21, 2024, 3:51 PM EDT) -- WASHINGTON, D.C. — A pharmaceutical company is disputing findings by the Patent Trial and Appeal Board (PTAB or board) that its patented form of polymorphic fingolimod hydrochloride is anticipated by prior art, telling the Federal Circuit U.S. Court of Appeals that along the way, the board “ignored” a key limitation which is “indisputably absent from the prior art.”...